Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis-Reference-Cited by-同舟云学术

Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis

Published:2019-12 Issue:6 Volume:54 Page:790-797
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Nguyen Chi Phuong,Dan Do Thuc Nguyen,Bruggemann Roger,ten Oever Jaap,Kolwijck Eva,Adang Eddy M.M.,Wertheim Heiman F.L.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference40 articles.

1. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States;Bartsch;Clin Microbiol Infect,2017

2. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections;Falagas;Emerg Infect Dis,2014

3. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands;Ir,2017

4. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections;Tamma;Clin Infect Dis,2017

5. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli;Retamar;Antimicrob Agents Chemother,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finding value in novel antibiotics: How can infectious diseases adopt incremental cost-effectiveness to improve new antibiotic utilization?;Diagnostic Microbiology and Infectious Disease;2024-06

2. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model;HEALTH TECHNOL ASSES;2024

3. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study;Journal of Infection and Chemotherapy;2024-01

4. Budget impact analysis of temocillin insurance coverage for urinary tract infections caused by ESBL-producing pathogens in Iran;Medicine;2023-09-01

5. Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials;International Journal of Antimicrobial Agents;2023-08